Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Bolt Biotherapeutics Announced That Updated Clinical Data From Its Phase 1/2 Dose-escalation Study Of BDC-1001 Will Be Presented In A Mini-oral Presentation At The European Society For Medical Oncology Congress 2023

Author: Benzinga Newsdesk | October 16, 2023 07:31am

Posted In: BOLT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist